Introduction Grip strength and walking pace have been linked to cognitive dysfunction. Their relationships, however, demand further clarification as the evidence is derived primarily from less‐comprehensive investigations. Methods A total of 340212 UK Biobank participants without dementia and cardiovascular diseases at baseline were analyzed. Cox proportional hazard models assessed the longitudinal associations. Results Over a mean follow‐up of 8.51 ± 2.68 years, 2424 incident dementia cases were documented. A 5 kg increment of absolute grip strength was associated with lower risks of all‐cause dementia (hazard ratio [HR] 0.857), Alzheimer's disease (HR 0.874), and vascular dementia (HR 0.788). The patterns of associations remained similar when grip strength was expressed in relative terms and quintiles. A slow walking pace demonstrated consistent associations with increased risks of all dementia types. Discussion Our findings provide amplified evidence and suggest that muscle fitness, reflected by objective grip strength measures and self‐reported walking pace, may be imperative for estimating the risks of dementia.
BackgroundThe formation of isoAsp via spontaneous asparagine (Asn) deamidation or aspartate (Asp) isomerization has been regarded as a molecular clock of aging that significantly correlates with neurodegenerative diseases (NDDs). Our earlier findings established a strong link between isoAsp and Alzheimer’s disease (AD). In this study, we aimed at validating the diagnostic value of blood isoAsp‐related biomarkers for NDD prediction.MethodsThe levels of isoAsp in plasma human serum albumin (HSA) and the immunoglobulin G (IgG) specific against artificially aged HSA were measured in two cohorts by indirect enzyme‐linked immunosorbent assay (ELISA). Cohort 1 contained patients with AD and controls, while Cohort 2 recruited subjects with mild cognitive impairment (MCI), vascular dementia (VD), frontotemporal dementia (FTD), Parkinson disease (PD) and healthy controls. Apart from the memory tests, other plasma biomarkers reported in literature were quantified as well, including amyloid beta (Aβ) peptides Aβ40 and Aβ42, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP) and phosphorylated Tau 181 (pTau181) protein.ResultsCohort 1 confirmed as expected a significant increase of isoAsp in HSA and reduction of IgG against aged HSA in AD group compared to controls (P < 0.0001). Cohort 2 revealed similar trends in comparisons between controls and subjects of different NDDs (P < 0.05). The most exciting finding was the best performance of isoAsp‐related biomarkers in MCI prediction among all blood biomarkers. In addition, the levels of our biomarkers were strongly associated with the memory test scores (P < 0.01).ConclusionWe demonstrated the diagnostic capacity of isoAsp‐related biomarkers in predicting NDDs at the early stage of disease. The biomarker levels correlated with cognitive decline, supporting their roles in NDD development. However, the specificity of these novel biomarkers seemed to be not limited to AD. Additional longitudinal studies with follow‐up data shall be conducted for validation of these findings.
Background: Central immunity components especially microglia in dementia have been well studied and corresponding immunotherapy gradually caught the attention.However, few studies focused on peripheral immunity and dementia. Method:To address the issue, we examined the longitudinal association between incident dementia and peripheral immunity markers encompassing immune cell counts, and their derived ratios including neutrophil-to-lymphocyte ratio (NLR), platelet-tolymphocyte ratio (PLR), systemic immune-inflammation index (SII) and lymphocyteto-monocyte ratio (LMR), utilizing data of 361653 participants from the UK Biobank (UKB).Result: During a median follow-up of 8.99 years, 4239 participants developed dementia. The results revealed that increased innate immunity markers were associated with higher dementia risk (per SD increment hazard ratio [HR]; 95% confidence interval [CI]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.